Scholarlink

<p>In this study, we measured the inhibitory potential of six coumarins against aldose reductase using both computational and experimental approaches. Molecular docking, molecular dynamics simulations, and MM/PBSA binding free energy calculations identified auraptene, marmesin, and isopimpinellin as the most promising inhibitors, with binding affinities of ΔG = −34.88, −29.40, and −20.31 kcal/mol, respectively. ADMET analysis indicated favorable pharmacokinetic properties for all three compounds, including high gastrointestinal absorption and bioavailability. In vitro assays confirmed auraptene as the most potent inhibitor with the lowest IC<sub>50</sub> (1.43 ± 0.14 µM), outperforming quercetin (IC<sub>50</sub> = 2.50 ± 0.31 µM). Marmesin and isopimpinellin showed IC<sub>50</sub> values of 3.80 ± 0.1 µM and 5.71 ± 0.8 µM, respectively. Kinetic studies revealed auraptene as a noncompetitive inhibitor (K<sub>i</sub> = 1.84 µM), isopimpinellin as a competitive inhibitor (K<sub>i</sub> = 1.83 µM), and marmesin as a mixed inhibitor (K<sub>i</sub> = 2.32 µM). These results suggest auraptene and marmesin as potential lead compounds for AR inhibition with strong binding affinities and favorable pharmacokinetic profiles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multi-pronged approaches to the mechanism-based inactivation of aldose reductase by natural coumarins: molecular insights and experimental validation

  • 期刊论文

  • 发表日期：

    2025年5月15日

查看全文
  • Emadeldin M. Kamel,
  • Sarah I. Othman,
  • Faris F. Aba Alkhayl,
  • Fahad M. Alshabrmi,
  • Ahmed A. Allam,
  • Noha A. Ahmed,
  • Al Mokhtar Lamsabhi

摘要

In this study, we measured the inhibitory potential of six coumarins against aldose reductase using both computational and experimental approaches. Molecular docking, molecular dynamics simulations, and MM/PBSA binding free energy calculations identified auraptene, marmesin, and isopimpinellin as the most promising inhibitors, with binding affinities of ΔG = −34.88, −29.40, and −20.31 kcal/mol, respectively. ADMET analysis indicated favorable pharmacokinetic properties for all three compounds, including high gastrointestinal absorption and bioavailability. In vitro assays confirmed auraptene as the most potent inhibitor with the lowest IC50 (1.43 ± 0.14 µM), outperforming quercetin (IC50 = 2.50 ± 0.31 µM). Marmesin and isopimpinellin showed IC50 values of 3.80 ± 0.1 µM and 5.71 ± 0.8 µM, respectively. Kinetic studies revealed auraptene as a noncompetitive inhibitor (Ki = 1.84 µM), isopimpinellin as a competitive inhibitor (Ki = 1.83 µM), and marmesin as a mixed inhibitor (Ki = 2.32 µM). These results suggest auraptene and marmesin as potential lead compounds for AR inhibition with strong binding affinities and favorable pharmacokinetic profiles.